Jiang J, Li A H, Jang S Y, Chang L, Melman N, Moro S, Ji X, Lobkovsky E B, Clardy J C, Jacobson K A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
J Med Chem. 1999 Aug 12;42(16):3055-65. doi: 10.1021/jm980688e.
Racemic 6-phenyl-4-phenylethynyl-1,4-dihydropyridine derivatives have been shown to be highly selective A(3) adenosine receptor antagonists (Jiang et al. J. Med. Chem. 1997, 40, 2596-2608). Methods for resolving the optical isomers at the C4 position, involving selective crystallization or chromatographic separation of diastereomeric ester derivatives, have been developed. Optically pure glycerol and threitol derivatives were used as chiral auxiliary groups for ester formation at the 3-position, resulting in diastereomeric mixtures of dihydropyridines. Esterification of a 6-phenyl-4-phenylethynyl-1,4-dihydropyridine derivative at the 3-position with a chiral, protected glycerol moiety, (S)-(+)-2, 2-dimethyl-1,3-dioxolane-4-methanol, allowed the selective crystallization of a pure diastereomer, 9. The (1)H NMR spectrum of 9 using the lanthanide shift reagent Eu(fod)(3) indicated optical purity, and the (4S,2'R)-configuration was assigned using X-ray crystallography. The noncrystalline (4R,2'R)-isomer 10 was also isolated and shown to be 3-fold more potent than the (4S,2'R)-isomer in binding to A(3) receptors. The 2,2-dimethyl-1,3-dioxolane moiety also served as a protected form of a diol, which showed selective reactivity versus a 5-ethyl ester in basic transesterification reactions. A racemic 5-carboxylic acid derivative could not be resolved through crystallization of diastereomeric salts. Enantiomers of 5-benzyl 3-ethyl 2-methyl-6-phenyl-4-phenylethynyl-1, 4-dihydropyridine-3,5-dicarboxylate (2) were obtained via an ester derived from (4R,5R)-(-)-2,3-O-isopropylidene-D-threitol at the 3-position, which was resolved using HPLC, and each diastereomer was subsequently deprotected in acidic conditions. The resulting diols were exchanged for ethyl ester groups by base-catalyzed transesterification. The binding of pure enantiomers of 2 at A(3) adenosine receptors indicated a 35-fold stereoselectivity for the (4S)-isomer 21. A receptor docking hypothesis, using a previously derived human A(3) receptor model, shows the bulkier of the two ester groups (5-Bn) of 21 oriented toward the exofacial side and the 4-position phenylethynyl group situated between transmembrane helical domain TM6 and TM7.
消旋6-苯基-4-苯乙炔基-1,4-二氢吡啶衍生物已被证明是高选择性的A₃腺苷受体拮抗剂(Jiang等人,《药物化学杂志》,1997年,40卷,2596 - 2608页)。已开发出在C4位拆分光学异构体的方法,该方法涉及非对映体酯衍生物的选择性结晶或色谱分离。光学纯的甘油和苏糖醇衍生物用作3位酯形成的手性辅助基团,从而得到二氢吡啶的非对映体混合物。用手性保护的甘油部分(S)-(+)-2,2 - 二甲基 - 1,3 - 二氧戊环 - 4 - 甲醇对6 - 苯基 - 4 - 苯乙炔基 - 1,4 - 二氢吡啶衍生物在3位进行酯化,可使纯非对映体9选择性结晶。使用镧系位移试剂Eu(fod)₃得到的9的¹H NMR谱表明其光学纯度,并通过X射线晶体学确定其为(4S,2'R)构型。非结晶的(4R,2'R)异构体10也被分离出来,并且在与A₃受体结合方面显示出比(4S,2'R)异构体强3倍的活性。2,2 - 二甲基 - 1,3 - 二氧戊环部分也用作二醇的保护形式,在碱性酯交换反应中,它对5 - 乙酯显示出选择性反应性。消旋5 - 羧酸衍生物不能通过非对映体盐的结晶来拆分。5 - 苄基3 - 乙基2 - 甲基 - 6 - 苯基 - 4 - 苯乙炔基 - 1,4 - 二氢吡啶 - 3,5 - 二羧酸酯(2)的对映体是通过在3位衍生自(4R,5R)-(-)-2,3 - O - 异丙叉基 - D - 苏糖醇的酯获得的,该酯通过HPLC拆分,随后每种非对映体在酸性条件下脱保护。通过碱催化的酯交换将所得二醇换成乙酯基团。2的纯对映体在A₃腺苷受体上的结合表明对(4S)-异构体21具有35倍的立体选择性。使用先前推导的人A₃受体模型的受体对接假说表明,21的两个酯基团中较大的一个(5 - Bn)朝向外侧,4 - 位苯乙炔基位于跨膜螺旋结构域TM6和TM7之间。